1. INTRODUCTION
1.1. Market Overview
1.2. Scope of the Study
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY SAMPLE TISSUE
5.1. Introduction
5.2. Blood
5.3. Urine
5.4. Saliva
5.5. Others
6. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY BIOMARKERS
6.1. Introduction
6.2. Circulating Tumor Cells (CTCs)
6.3. Circulating Tumor DNA (ctDNA)
6.4. Cell-Free DNA (cfDNA)
6.5. Extracellular Vesicles (EVs)
6.6. Others
7. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY APPLICATION
7.1. Introduction
7.2. Screening
7.3. Disease Prognosis
7.4. Drug Response & Resistance
8. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. UK
8.4.4. Italy
8.4.5. Spain
8.4.6. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. South Africa
8.5.4. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES 
10.1. F. Hoffmann-La Roche AG
10.2. Bio-Rad Laboratories, Inc.
10.3. Genomic Health, Inc.
10.4. Qiagen N.V.
10.5. NeoGenomics Laboratories, Inc.
10.6. Biocept, Inc.
10.7. LungLife AI, Inc.
10.8. Illumina, Inc.
10.9. Cardiff Oncology
10.10. Guardant Health, Inc.